Literature DB >> 6390194

Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone.

C L Mendenhall, S Anderson, P Garcia-Pont, S Goldberg, T Kiernan, L B Seeff, M Sorrell, C Tamburro, R Weesner, R Zetterman.   

Abstract

A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen per cent of the moderately ill patients and 29 per cent of the severely ill patients died. Although neither steroid improved short-term survival, oxandrolone therapy was associated with a beneficial effect on long-term survival. This was especially true in patients with moderate disease: among those who survived for one or two months after the start of treatment the conditional six-month death rate was 3.5 per cent after oxandrolone and 19 to 20 per cent after placebo (P = 0.02). No consistent long-term effect was associated with prednisolone therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6390194     DOI: 10.1056/NEJM198412063112302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  Future use of the Glasgow alcoholic hepatitis score.

Authors:  I N Guha; W M Rosenberg
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 3.  Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease.

Authors:  C S Lieber
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

5.  Alcoholic Hepatitis.

Authors:  Kester I. Crosse; Frank A. Anania
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

Review 6.  Propylthiouracil for alcoholic liver disease.

Authors:  Giuseppe Fede; Giacomo Germani; Christian Gluud; Kurinchi Selvan Gurusamy; Andrew K Burroughs
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 7.  Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials.

Authors:  Chao-Hui Yu; Cheng-Fu Xu; Hua Ye; Lan Li; You-Ming Li
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

8.  Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.

Authors:  E H Forrest; C D J Evans; S Stewart; M Phillips; Y H Oo; N C McAvoy; N C Fisher; S Singhal; A Brind; G Haydon; J O'Grady; C P Day; P C Hayes; L S Murray; A J Morris
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

9.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

Review 10.  Advances in alcoholic liver disease: An update on alcoholic hepatitis.

Authors:  Randy Liang; Andy Liu; Ryan B Perumpail; Robert J Wong; Aijaz Ahmed
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.